## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

## <u>Listing of Claims</u>:

1. (Currently Amended) A compound of formula I:

$$R_1$$
 $N$ 
 $X$ 
 $SO_2R_3$ 

Ι

## wherein:

one of X or Y represents N and the other represents C;  $R_1 \ \text{represents hydrogen, methyl, halogen, cyano, nitro, -CHO,} \\ -\text{COCH}_3 \ \text{or } -\text{COOR}_4;$ 

 $R_2$  represents aryl or heteroaryl unsubstituted or substituted with one or more groups independently selected from halogen,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $R_4OC_{0-8}$  alkyl,  $R_4SC_{0-8}$  alkyl, cyano, nitro, -  $NR_4R_6$ , - $NR_4SO_2R_5$ , - $SO_2R_5$ , - $SO_2NR_4R_6$ , or - $CONR_4R_6$ ;  $R_3$  represents  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl or - $NR_4R_6$ ;

 $R_4$  represents hydrogen,  $C_{1-8}$  alkyl, or  $arylC_{0-8}$  alkyl (where the aryl group can be unsubstituted or substituted with one or more groups selected from  $C_{1-8}$  alkyl, halogen,  $C_{1-8}$  haloalkyl, cyano, nitro,  $R_7OC_{0-8}$  alkyl,  $R_7SC_{0-8}$  alkyl,  $-NR_7R_8$ ,  $-NR_7COR_5$ ,  $-COR_7$  or  $-COOR_7$ );

 $R_5$  represents  $C_{1-8}$  alkyl or  $C_{1-8}$  haloalkyl;

 $R_6$  represents hydrogen,  $C_{1-8}$  alkyl, aryl $C_{1-8}$  alkyl (where the aryl group can be unsubstituted or substituted with one or more groups selected from  $C_{1-8}$  alkyl, halogen,  $C_{1-8}$  haloalkyl, cyano, nitro,  $R_7OC_{0-8}$  alkyl,  $R_7SC_{0-8}$  alkyl,  $-NR_7R_8$ ,  $-NR_7COR_5$ ,  $-COR_7$  or  $-COOR_7$ ),  $-COR_8$  or  $-COOR_8$ ;

 $R_7$  represents hydrogen,  $C_{1-8}$  alkyl or benzyl;

 $R_8$  represents  $C_{1-8}$  alkyl or  $C_{1-8}$  haloalkyl;

aryl in the above definitions represents phenyl or naphthyl; and heteroaryl in the above definitions represents pyridine, pyrazine, pyrimidine or pyridazine, which can be optionally fused to a benzene ring;

or a salt, solvate or prodrug thereof.

- 2. (Original) A compound according to claim 1 wherein  $R_1$  represents halogen.
- 3. (Original) A compound according to claim 2 wheren  $R_1$  represents chloro.
- 4. (Currently Amended) A compound according to claim 1 wherein  $R_2$  represents phenyl or pyridine unsubstituted or

substituted with one or more groups independently selected from halogen,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $R_4OC_{0-8}$  alkyl,  $R_4SC_{0-8}$  alkyl, cyano, nitro,  $-NR_4R_6$ ,  $-NR_4SO_2R_5$ ,  $-SO_2R_5$ ,  $-SO_2R_5$ ,  $-SO_2NR_4R_6$ , or  $-CONR_4R_6$ .

- 5. (Original) A compound according to claim 1 wherein  $R_3$  represents methyl or  $-NH_2$ .
- 6. (Original) A compound according to claim 1 wherein X represents N.
- 7. (Original) A compound according to claim 5 wherein  $R_1$  represents halogen.
- 8. (Original) A compound according to claim 5 wherein  $R_1$  represents chloro.
- 9. (Original) A compound according to claim 7 or 8 wherein X represents N.
- 10. (Currently Amended) A compound according to claim 9 wherein  $R_2$  represents phenyl or pyridine unsubstituted or substituted with one or more groups independently selected from halogen,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $R_4OC_{0-8}$  alkyl,  $R_4SC_{0-8}$  alkyl, cyano, nitro,  $-NR_4R_6$ ,  $-NR_4SO_2R_5$ ,  $-SOR_5$ ,  $-SO_2R_5$ ,  $-SO_2NR_4R_6$ , or  $-CONR_4R_6$ .
- 11. (Currently Amended) A compound according to claim 1
  selected from:
- 5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)imidazole; 5-(4-methylphenyl)-1-(4-methylsulfonylphenyl)imidazole;

```
5-(2,4-difluorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
1-(4-methylsulfonylphenyl)-5-phenylimidazole;
5-(3,4-dichlorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(4-methoxyphenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(3-fluoro-4-methoxyphenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(3-fluorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(3-fluoro-4-methylphenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(2-fluorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
1-(4-methylsulfonylphenyl)-5-(4-trifluoromethoxyphenyl)imidazole;
5-(6-methyl-3-pyridyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(2-fluoro-4-methoxyphenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(3-chloro-4-methylphenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(3-methoxy-4-methylphenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(4-chlorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(6-chloro-3-pyridyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(2,6-dichloro-3-pyridyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(2-chloro-6-methoxy-3-pyridyl)-1-(4-
methylsulfonylphenyl)imidazole;
5-(5,6-dichloro-3-pyridyl)-1-(4-methylsulfonylphenyl)imidazole;
1-(4-methylsulfonylphenyl)-5-(4-propoxyphenyl)imidazole;
5-(3,5-diethoxyphenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(4-ethoxyphenyl)-1-(4-methylsulfonylphenyl)imidazole;
1-(4-methylsulfonylphenyl)-5-(4-nitrophenyl)imidazole;
5-(4-methylsulfanylphenyl)-1-(4-methylsulfonylphenyl)imidazole;
```

```
5-(4-ethylsulfanylphenyl)-1-(4-methylsulfonylphenyl)imidazole;
5-(4-dimethylaminophenyl)-1-(4-methylsulfonylphenyl)imidazole;
1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)imidazole;
5-(4-fluorophenyl)-4-methyl-1-(4-methylsulfonylphenyl)imidazole;
4-chloro-5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
4-chloro-5-(4-methylphenyl)-1-(4-methylsulfonylphenyl)imidazole;
4-chloro-5-(2,4-difluorophenyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-1-(4-methylsulfonylphenyl)-5-phenylimidazole;
4-chloro-5-(3,4-dichlorophenyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(4-methoxyphenyl)-1-(4-methylsulfonylphenyl)imidazole;
4-chloro-5-(3-fluoro-4-methoxyphenyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(3-fluorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
4-chloro-5-(3-fluoro-4-methylphenyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(2-fluorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
4-chloro-1-(4-methylsulfonylphenyl)-5-(4-
trifluoromethoxyphenyl)imidazole;
4-chloro-5-(6-methyl-3-pyridyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(2-fluoro-4-methoxyphenyl)-1-(4-
methylsulfonylphenyl)imidazole;
```

```
4-chloro-5-(3-chloro-4-methylphenyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(3-methoxy-4-methylphenyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(4-chlorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
4-chloro-5-(6-chloro-3-pyridyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(2;6-dichloro-3-pyridyl)-1-(4-
methylsulfonylphenyl) imidazole;
4-chloro-5-(2-chloro-6-methoxy-3-pyridyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(5,6-dichloro-3-pyridyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-1-(4-methylsulfonylphenyl)-5-(4-propoxyphenyl)imidazole;
4-chloro-5-(3,5-diethoxyphenyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(4-ethoxyphenyl)-1-(4-methylsulfonylphenyl)imidazole;
4-chloro-1-(4-methylsulfonylphenyl)-5-(4-nitrophenyl)imidazole;
4-chloro-5-(4-methylsulfanylphenyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(4-ethylsulfanylphenyl)-1-(4-
methylsulfonylphenyl)imidazole;
4-chloro-5-(6-ethoxy-3-pyridyl)-1-(4-
methylsulfonlyphenyl)imidazole;
```

```
4-bromo-5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)imidazole;
1-(4-fluorophenyl)-2-methyl-5-(4-methylsulfonylphenyl)imidazole;
2-chloro-1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)imidazole;
1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)imidazol-2-
carboxaldehyde;
methyl 1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)imidazol-2-
carboxylate;
2-bromo-1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)imidazole;
1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)imidazol-2-
carbonitrile;
2-chloro-5-(4-methylsulfonlyphenyl)-1-phenylimidazole;
2-chloro-1-(4-methylphenyl)-5-(4-methylsulfonylphenyl)imidazole;
4-[4-chloro-5-(4-fluorophenyl)imidazol-1-yl]benzenesulfonamide;
4-(4-chloro-5-phenylimidazol-1-yl)benzenesulfonamide;
4-[4-chloro-5-(3,4-dichlorophenyl)imidazol-1-
yl]benzenesulfonamide;
4-[4-chloro-5-(4-methylphenyl)imidazol-1-yl]benzenesulfonamide;
4-[4-chloro-5-(4-ethoxyphenyl)imidazol-1-yl]benzenesulfonamide;
4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-
yl]benzenesulfonamide;
4-[4-chloro-5-(6-chloro-3-pyridyl)imidazol-1-
yl]benzenesulfonamide;
4-[5-(4-fluorophenyl)imidazol-1-yl]benzenesulfonamide;
5-(4-aminophenyl)-4-chloro-1-(4-methylsulfonylphenyl)imidazole;
```

5 (6 ethoxy-3-pyridyl)-1 (4-methylsulfonylphenyl)imidazole;

4-chloro-5-(4-dimethylaminophenyl)-1-(4-

methylsulfonylphenyl)imidazole;

5-(3-chloro-4-dimethylaminophenyl)-1-(4-

methylsulfonylphenyl)imidazole;

4-chloro-5-(3-chloro-4-dimethylaminophenyl)-1-(4-

methylsulfonylphenyl)imidazole;

5-(4-acetylaminophenyl)-4-chloro-1-(4-

methylsulfonylphenyl)imidazole;

5-(4-ethylsulfinylphenyl)-1-(4-methylsulfonylphenyl)imidazole;

5-(4-ethylsulfonylphenyl)-1-(4-methylsulfonylphenyl)imidazole;

- a salt thereof;
- a solvate thereof; and
- a prodrug thereof.
- 12. (Previously presented) A process for preparing a compound of formula I according to claim 1 which comprises:
- (a) when in a compound of formula I  $R_1$  represents hydrogen or methyl, reacting an imine of formula II

wherein X, Y,  $R_2$  and  $R_3$  are as defined in claim 1, with an isocyanide of formula III

$$\underset{R_1}{\overset{L}{\bigvee}} \text{NC}$$

III

wherein  $R_1$  represents hydrogen or methyl and L represents a leaving group; or

(b) when in a compound of formula I  $R_3$  represents  $C_{1-8}$  alkyl or  $C_{1-8}$  haloalkyl, oxidizing a thioether of formula VIII,

$$R_1$$
 $Y$ 
 $R_2$ 
 $SR_3$ 

wherein  $R_3$  represents  $C_{1-8}$  alkyl or  $C_{1-8}$  haloalkyl and X, Y,  $R_1$  and  $R_2$  are as defined in claim 1, with an oxidizing agent; or (c) when in a compound of formula I  $R_3$  represents  $-NH_2$ , reacting a compound of formula IX

$$R_1$$
  $Y$   $R_2$   $Y$   $SO_2Na$ 

wherein X, Y,  $R_1$  and  $R_2$  are as defined in claim 1, with hydroxylamine-O-sulfonic acid; or

ΙX

(d) when in a compound of formula I  $\ensuremath{R_3}$  represents -NR\_4R\_6, reacting a compound of formula XI

wherein X, Y,  $R_1$  and  $R_2$  are as defined in claim 1, with an amine of formula  $HNR_4R_6$ ; or

- (e) when in a compound of formula I  $R_1$  represents halogen and X represents N, reacting a compound of formula I wherein  $R_1$  represents hydrogen with a halogenating agent; or
- (f) when in a compound of formula I  $R_1$  represents halogen and Y represents N, reacting a compound of formula I wherein  $R_1$  represents hydrogen with a strong base and a halogenating agent; or
- (g) converting a compound of formula I into another compound of formula I.
- 13. (Original) A pharmaceutical composition which comprises an effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug

thereof in admixture with one or more pharmaceutically acceptable excipients.

## 14-27. (Cancelled)

- 28. (Original) A method of treating inflammation, pain or fever in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- 29. (Original) A method in accordance with claim 28, wherein said mammal is a human.
- 30. (Previously presented) A method for treating prostanoid-induced smooth muscle contraction in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- 31. (Original) A method in accordance with claim 30, wherein said mammal is a human.
- 32. (Previously presented) A method of treating dysmenorrhea, preterm labor, asthma or bronchitis in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof.

- 33. (Original) A method in accordance with claim 32, wherein said mammal is a human.
- 34. (Currently amended) A method of treating liver, bladder, pancreas, ovary, prostate, cervix, lung, breast, skin or gastrointestinal and colon cancer in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- 35. (Previously Presented) A method in accordance with claim 34, wherein said mammal is a human.
- 36. (Original) A method according to claim 34 or 35, wherein said cancer is a gastrointestinal cancer.
- 37. (Original) A method according to claim 36, wherein said cancer is colon cancer.
- 38. (Currently amended) A method of treating cerebral infarction, infarction or epilepsy in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- 39. (Original) A method according to claim 38, wherein said mammal is a human.

40. (Currently amended) A method of treating Alzheimer's disease or dementia in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I, according to claim 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof is Alzheimer's disease or dementia.